Neotigason (Acitretin)

Acitretin, the active ingredient in Neotigason, is a retinoid presented as an oral tablet for oral use. It is prescribed for severe forms of psoriasis and other keratinization disorders in adults. GNH USA supplies Neotigason as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neotigason, a retinoid, is indicated for disorders characterized by abnormal keratinocyte proliferation.

Severe plaque psoriasis: reduces scaling and plaque thickness by normalizing keratinocyte differentiation. Pustular psoriasis: controls widespread pustular eruptions and accelerates lesion clearance. Other keratinization disorders: improves skin texture and reduces hyperkeratosis in conditions such as ichthyosis.

Acitretin may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Dry skin: increased epidermal dryness and scaling. - Hair loss: temporary alopecia. - Elevated liver enzymes: mild rise in transaminases.

Serious or Rare Side Effects: - Severe liver injury: hepatitis or hepatic failure. - Pancreatitis: acute inflammation of the pancreas. - Skeletal toxicity: premature epiphyseal closure in children or adults with prolonged use.

Neotigason requires careful monitoring and specific safety measures.

Pregnancy: contraindicated due to high teratogenic risk (Category X). Contraception: effective contraception required for women of childbearing potential during treatment and for at least three years after discontinuation. Liver function: monitor hepatic enzymes before and during therapy. Lipid profile: assess triglycerides and cholesterol regularly. Bone health: avoid use in growing children; monitor skeletal development. Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Acitretin can interact with several medicines, necessitating vigilance.

Major Interactions (Avoid): - Tetracyclines: increased risk of intracranial hypertension. - Vitamin A supplements: additive toxicity. - Methotrexate: enhanced hepatotoxicity.

Moderate Interactions (Monitor Closely): - Oral contraceptives: reduced efficacy, require additional barrier methods. - Statins: potential increase in lipid abnormalities. - Anticoagulants: possible alteration of INR.